tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ZNTL Stock Latest News

Zentalis board member Letai frontrunner to lead NCI, STAT reports
The FlyZentalis board member Letai frontrunner to lead NCI, STAT reports
9d ago
ZNTL
Zentalis Pharmaceuticals Announces New Chief Legal Officer
PremiumCompany Announcements
Zentalis Pharmaceuticals Announces New Chief Legal Officer
1M ago
8K
ZNTL
Zentalis CLO Andrea Paul to depart, James Bucher to succeed
PremiumThe Fly
Zentalis CLO Andrea Paul to depart, James Bucher to succeed
1M ago
ZNTL
Zentalis price target lowered to $5 from $6 at Wells Fargo
PremiumThe Fly
Zentalis price target lowered to $5 from $6 at Wells Fargo
2M ago
ZNTL
Strategic Advancements and Promising Clinical Data Support Buy Rating for Zentalis Pharmaceuticals
PremiumRatings
Strategic Advancements and Promising Clinical Data Support Buy Rating for Zentalis Pharmaceuticals
2M ago
ZNTL
Zentalis Pharmaceuticals: Hold Rating Amid Delayed Catalysts and Market Skepticism
PremiumRatingsZentalis Pharmaceuticals: Hold Rating Amid Delayed Catalysts and Market Skepticism
2M ago
ZNTL
Zentalis Pharmaceuticals Reports Improved Financial Results
Premium
Company Announcements
Zentalis Pharmaceuticals Reports Improved Financial Results
2M ago
ZNTL
Zentalis Pharmaceuticals Reports Q2 2025 Financial Results
Premium
Company Announcements
Zentalis Pharmaceuticals Reports Q2 2025 Financial Results
2M ago
8K
ZNTL
Zentalis management to meet with Oppenheimer
PremiumThe Fly
Zentalis management to meet with Oppenheimer
3M ago
ZNTL
Zentalis Pharmaceuticals Holds 2025 Annual Stockholders Meeting
PremiumCompany Announcements
Zentalis Pharmaceuticals Holds 2025 Annual Stockholders Meeting
4M ago
8K
ZNTL
Zentalis Pharmaceuticals Presents Promising Study Results at ASCO
PremiumCompany Announcements
Zentalis Pharmaceuticals Presents Promising Study Results at ASCO
4M ago
8K
ZNTL
Promising Phase 1 Results and Strong Efficacy Signals Drive Buy Rating for Zentalis Pharmaceuticals’ Azenosertib
PremiumRatings
Promising Phase 1 Results and Strong Efficacy Signals Drive Buy Rating for Zentalis Pharmaceuticals’ Azenosertib
4M ago
ZNTL
Zentalis Pharmaceuticals at H.C. Wainwright BioConnect Conference
PremiumCompany AnnouncementsZentalis Pharmaceuticals at H.C. Wainwright BioConnect Conference
5M ago
8K
ZNTL
Cautious Outlook on Zentalis Pharmaceuticals Amid Strategic Focus and Financial Management
Premium
Ratings
Cautious Outlook on Zentalis Pharmaceuticals Amid Strategic Focus and Financial Management
5M ago
ZNTL
Zentalis Pharmaceuticals: Strategic Advancements and Promising Clinical Outcomes Justify Buy Rating
Premium
Ratings
Zentalis Pharmaceuticals: Strategic Advancements and Promising Clinical Outcomes Justify Buy Rating
5M ago
ZNTL
Zentalis Pharmaceuticals Reports Q1 2025 Financial Results
PremiumCompany Announcements
Zentalis Pharmaceuticals Reports Q1 2025 Financial Results
5M ago
ZNTL
Zentalis price target lowered to $9 from $10 at Oppenheimer
PremiumThe Fly
Zentalis price target lowered to $9 from $10 at Oppenheimer
5M ago
ZNTL
Zentalis Pharmaceuticals: Hold Rating Maintained Amid Lack of Short-Term Catalysts and Stock Decline
PremiumRatings
Zentalis Pharmaceuticals: Hold Rating Maintained Amid Lack of Short-Term Catalysts and Stock Decline
5M ago
ZNTL
Zentalis Pharmaceuticals: Promising Clinical Trials and Potential for Accelerated Approval Justify Buy Rating
PremiumRatings
Zentalis Pharmaceuticals: Promising Clinical Trials and Potential for Accelerated Approval Justify Buy Rating
5M ago
ZNTL
Zentalis reports Q1 EPS (67c), consensus (61c)
PremiumThe FlyZentalis reports Q1 EPS (67c), consensus (61c)
5M ago
ZNTL
Zentalis announces first patient dosed in DENALI Part 2 trial of azenosertib
Premium
The Fly
Zentalis announces first patient dosed in DENALI Part 2 trial of azenosertib
5M ago
ZNTL
Zentalis Highlights Azenosertib Findings at 2025 AACR
Premium
Company Announcements
Zentalis Highlights Azenosertib Findings at 2025 AACR
5M ago
8K
ZNTL

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >